论文部分内容阅读
CV205-502即八氢苯并喹啉是一种新型的非麦角类长效多巴胺促效剂。在所有动物模型中都表明能有效地抑制催乳素分泌。作者通过临床实验疗效观察,第一次报道CV205-502对治疗高催乳素血症中的结果。 病例与方法:24例女性高催乳素血症患者,年龄18-47岁。这些患者都曾有过长达6-132个月的闭经史,除3例来曾用过任何多巴胺促效剂治疗外,其他患者曾用溴隐亭治疗2-69个月,但在开始CV205-502治疗至少1个月之前停用溴隐亭。在
CV205-502 octahydrobenzoquinoline is a new non-ergot class of long-acting dopamine agonist. In all animal models have shown that can effectively inhibit prolactin secretion. The author through the clinical trial of efficacy, the first report of CV205-502 on the treatment of hyperprolactinemia in the results. Cases and Methods: 24 cases of female hyperprolactinemia patients, aged 18-47 years. All of these patients had amenorrhea history of 6-132 months. Except for 3 cases who had been treated with any dopamine agonist, other patients had been treated with bromocriptine for 2-69 months. However, at the beginning of CV205 Bromocriptine was discontinued before treatment with -502 for at least 1 month. in